Navigation Links
ClearTrial Unveils New Product Release at Partnerships in Clinical Trials Conference 2010

ClearTrial v3.2 Enables Organizations to Achieve Greater Control and Increased Accuracy When Managing Complex, Global Clinical Studies

Orlando, FL (PRWEB) April 12, 2010 -- ClearTrial (, the leading provider of Clinical Trial Operations (CTO) software, today launched ClearTrial v3.2, a major upgrade to its award-winning ClearTrial PLAN, ClearTrial SOURCE, and ClearTrial TRACK products. ClearTrial v3.2 helps pharmaceutical, biotechnology and medical device companies meet the increasingly challenging demands of planning, sourcing, and tracking studies – challenges driven by a more complex and global clinical development environment.

"Our ongoing research indicates that clinical research protocols are being conducted in more global locations at the same time that they are increasingly more complex and demanding," said Kenneth Getz, Senior Research Fellow at the Tufts Center for the Study of Drug Development. "These factors present significant challenges to the industry as it strives to achieve higher levels of efficiency and productivity."

ClearTrial v3.2 is based on extensive industry research as well as comprehensive input from ClearTrial's global customer base, which ranges from the Top 20 sponsors to small biotech and medical device companies in the US, Europe, and Japan. The latest software release includes a number of new features and product enhancements that give trial sponsors more granular control over the clinical assumptions that drive study cost, resource demand, and timelines. These enhancements also provide for greater accuracy in forecasting – improving on the leading standard established by ClearTrial, which has been benchmarked to 1-5% accuracy when compared with actual study costs.

For global studies and for trial sponsors entering new and emerging countries to conduct trials, ClearTrial v3.2 expands on the software's already extensive, country-specific clinical intelligence. By including labor rates for each country, as well as intelligence around tasks affecting study timelines – such as site activation and regulatory delays – ClearTrial v3.2 makes it easier to model "what-if" scenarios and to generate fast and accurate forecasts of study costs, resource demand, and timelines in any region.

"As our customers’ clinical study processes become more global and more complex, the ClearTrial software continues to lead the market in support of such demands," said Mike Soenen, ClearTrial President and CEO. "ClearTrial v3.2 provides more flexibility in planning and tracking complex global studies while continuing to deliver on our promise to make certain our software is intuitive and easy to use for the wide range of organizations that we serve."

ClearTrial v3.2 New Features Summary

Flexible Enrollment Specification – ClearTrial v3.2 now provides both global and region-specific definition of study enrollment period and distribution. Enrollment distribution has been extended to allow weekly distributions. These new capabilities will enable the user to better accommodate differences in global enrollment performance.

Enhanced Site Approval Forecasting – ClearTrial v3.2 has enhanced its site approval forecasting capabilities to now allow region-specific site approval schedules and the definition of user defined site approval curves. These new features will allow the user to more accurately model site approval schedules.

Advanced Pass Through Costs Definition – ClearTrial v3.2 allows the user greater flexibility in defining pass through and miscellaneous costs. Costs can now be defined at a study or location level, be driven by specific study milestones, and be distributed based on pre-defined distribution curves. These new features will enable customers to more accurately assign and distribute pass through costs resulting in more precise forecasting and budgeting.

Expanded Country-specific Industry Intelligence – ClearTrial v3.2 expands the embedded clinical intelligence of the software to more than 80 countries worldwide. Featuring country-specific awareness for labor rates as well as for tasks affecting study timelines – such as site activation and regulatory delays – ClearTrial v3.2 supports the increasingly global nature of studies. This expanded capability makes it easier to model "what-if" scenarios that include the emerging countries and regions experiencing rapid growth in clinical trials.

Extended Global Currency Support – ClearTrial v3.2 has extended its global currency support to allow entry of alternate currencies for any study assumption that requires a monetary value. Alternate currencies are automatically converted based on predefined exchange rate conversion rules and on-demand reports can be printed in any currency of choice. These new capabilities will improve study planning in multiple geographies and eliminate manual and error prone currency conversions.

Reporting and Visualization – ClearTrial v3.2 delivers a host of additional tabular and graphical reports to its already extensive library of planning, forecasting and budgeting reports and graphs. These new reports will dramatically improve visibility across the lifecycle of a study.

About ClearTrial®
ClearTrial is the leading provider of Clinical Trial Operations (CTO) software, linking clinical planning, forecasting, and tracking of operational and financial performance in a single, integrated system. ClearTrial’s award-winning software helps life sciences companies streamline their clinical operations from Plan to Payment™ without sacrificing quality of results, providing executives and functional leaders in clinical operations, resource planning, finance, outsourcing, and project management with a common platform that promotes speed, accuracy, and consistency throughout the organization. For more information please visit

ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.

For more information contact:

Mike Lange
+1 630.986.9800 x112


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. ClearTrial to Demonstrate How a Top 20 Sponsor Achieved -1 Percent Cost Variance Across Their $130M Clinical Portfolio at Major Industry Conference
2. ClearTrial to Head Panel of Leading Wall Street Analysts at Pharmaceutical Accounting and Reporting Congress
3. ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies
4. ClearTrial Selected to Provide Methodologies for Accurately Forecasting and Budgeting Clinical Spend and Integrated Financial Controls at CBI Conference
5. ClearTrial to Demonstrate Dramatic Gains in Clinical Outsourcing Efficiency Achieved by Biopharmaceutical Companies at European Outsourcing Event
6. ClearTrial Names Proven Enterprise Software and Life Sciences Sales Leader Craig Smith as Vice President of Sales
7. ClearTrial Launches Industry-first Software Platform for Integrating Clinical Trial Operations from Plan to Cash™, Driving Operational Efficiencies and Accelerating Clinical Development
8. ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference
9. ClearTrial Industry Expert to Lead Session at DIA Annual Meeting on Improving Accrual and Contract Management in Clinical Trials
10. ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
11. ClearTrial Names Software Industry Veteran Michael Bruns as Chief Operating Officer
Post Your Comments:
(Date:11/24/2015)... Switzerland (PRWEB) , ... November 24, 2015 , ... ... plant and the environment are paramount. Insertion points for in-line sensors can represent ... has developed the InTrac 781/784 series of retractable sensor housings , which ...
(Date:11/24/2015)... 24, 2015 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: ... Mr. Pierre Laurin , President and Chief Executive Officer ... upcoming Piper Jaffray 27 th Annual Healthcare Conference to ... 1-2, 2015. st , at 8.50am (ET) ... throughout the day. The presentation will be available live via ...
(Date:11/24/2015)... 2015  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... president and chief executive officer, will present at the 27 ... New York City . The presentation will ... 2015 at 9:30 a.m. EST. and ... at least 15 minutes prior to the presentation to allow ...
(Date:11/24/2015)... Nov. 24, 2015 According to two new studies, ... This is something that many doctors, scientists, and public health ... remains: with fewer PSA tests being done, will there be ... Dr. David Samadi, "Despite the efforts made in ... the second leading cancer cause of death in men, killing ...
Breaking Biology Technology:
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):